Premier Alternatives

Inherent Biosciences

Salt Lake City, UT · Founded 2019 · Privately Held (backing)

Developer of an epigenetic medicine platform designed to tackle health issues by overhauling the trial-and-error methodology. Inherent Biosciences is based in Salt Lake City, UT and was founded in 2019. It was valued at $18.1 million at its early-stage round in Sep 2022, the last priced event on record. It has raised $9.8 million across 1 recorded round; the latest was a $1.5 million seed round in Aug 2022.

PMV mark · valuation
$18.1M
Oct 2026
Priced at
its early-stage round
Sep 2022
Total raised
$9.8M
Last round
Seed Round
Aug 2022

Inherent Biosciences key facts

as of Oct 2026
  • Developer of an epigenetic medicine platform designed to tackle health issues by overhauling the trial-and-error methodology.
  • Inherent Biosciences is valued at approximately $18.1M as of Oct 2026, set at its early-stage round, Sep 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $9.8M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Aug 2022.
  • Notable investors include US National Science Foundation, Endless Frontier Labs, Kickstart (US), Cadron Capital Partners, Samothrace Partners — 18 tracked in total.
  • Inherent Biosciences has filed 1 Form D with the SEC, most recently May 2023 ($1.5M sold to 12 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$18.1M

Valued at $18.1M at its early-stage round, Sep 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Inherent Biosciences with a free account
  • ·The complete investor list: 18 names
  • ·Watch Inherent Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Inherent Biosciences funding rounds

1 rounds
Aug 2022Seed Round$1.5MSEC filing▮
Full funding history →

Inherent Biosciences valuation

Inherent Biosciences was valued at $18.1 million at its early-stage round in Sep 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Inherent Biosciences raised?

Inherent Biosciences has raised $9.8 million in total; 1 of its rounds is on record. The largest on record was a $1.5 million seed round in Aug 2022.

Inherent Biosciences has filed 1 Form D with the SEC, most recently in May 2023 ($1.5 million sold to 12 investors).

Inherent Biosciences investors

18 investors are on record for Inherent Biosciences, including US National Science Foundation, Endless Frontier Labs, Kickstart (US) and Cadron Capital Partners. The seed round in Aug 2022 drew 12 investors.

About Inherent Biosciences

Developer of an epigenetic medicine platform designed to tackle health issues by overhauling the trial-and-error methodology. The company's platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics along with lifestyle effects on the probability of a positive reproduction, enabling doctors and physicians to guide patients with complex diseases.

Sector
Healthcare
HQ
Salt Lake City, UT, United States
Founded
2019
Employees
15
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.